Company Description

Samba BioLogics produce breakthrough agonist biologics that preserve tissue and improve repair after ischemic injury. Ther pipeline includes “Cell-Kro,” a biologic drug that promotes engraftment of transplanted progenitor cells, and “VasaPlex,” a biologic that rescues jeopardized cardiac tissue after myocardial infarction.